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inTrOducTiOn
MSCs are non-immortal multipotent cells, able to
form fibroblast-like colonies1. MSCs can differentiate
into osteoblasts, chondrocytes and adipocytes2, but
also into muscle cells, tenocytes, skeletal myocytes,
neurons and endothelial cells under the appropriate
in vitro inductive conditions3-5 .
Human MSCs are mainly isolated from bone mar-
row and adipose tissue, but also from amniotic fluid,
synovial tissue, skeletal and cardiac muscle, periosteum
and foetal tissues6-8. After isolation MSCs must be
cultured under sterile and strictly controlled conditions
in minimal medium supplemented with serum in tissue
culture plastic. After an initial delay, they start to pro-
liferate rapidly, depending on the tissue source, the
age, and the condition of the donor. 
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MSCs express a number of surface markers, even
though none of these is specific. They do not express
any hematopoietic markers, such as CD14, CD34 and
CD45. However, they express CD44, CD29, CD73,
CD90, CD166, CD105 and others6. MSCs are non-
immunogenic as they do not express MHCII, CD40
or CD80 (Table 1)10. 
In vivo studies have proven that injected MSCs
have the ability to engraft into healthy and injured
tissues with promising results for injury repair7. Their
beneficial effects rely either on their differentiation
potential into several cell types or on their ability to
locally promote tissue regeneration via an autocrine,
paracrine or juxtacrine action, without initiating an
immune respons11,12. Systemic delivery of MSCs has
also been reported by several groups, demonstrating
the trafficking, adhesion and engraftment of MSCs
to any site of injury13.
MSCs are capable to differentiate into chondro-
cytes in 3D culture systems in the presence of dexam-
ethasone, ascorbate and TGF-β14. Histological analysis
of chondrocytes shows positive staining with toluidine
blue15. Tissue engineered transplant describes the
process of reconstituting mammalian tissue, both
structurally and functionally. Such a process can be
achieved either entirely in vitro or partially in vitro
and then completed in vivo16. The process of tissue
engineering often begins with a scaffold which is a
three-dimensional structure. Cells are embedded in
the matrices or penetrating the scaffold and promote
tissue regeneration. There are many conventional
techniques for scaffold fabrication suffering from sev-
eral limitations, such as precise pore size, pore geom-
etry and high mechanical strength. 
Three-dimension printing can fabricate almost
any object geometry using a layer-by-layer building
method. It works as an ordinary 2D inkjet printer
(length, width) using height as the third dimension.
Furthermore, instead of ink as a material, it uses a
liquid binder solution that is deposited on a power
bed adding layers of the material to the designed struc-
ture. The methodology used to achieve 3D printed s-
caffolds starts with CAD (Computer Aided Design)
that must be drawn or taken from known organ struc-
tures. A different approach is by taking cross-sectional
slices and images from a computer tomography (CT)
where they can be compiled into a 3D image. Finally,
the designed geometry of the object can be produced
with CAM (Computer Aided Manufacturing).
Essential details regarding the optimal conditions,
tissue source and the matrix material, as well as clinical
safety and efficacy remain to be tested. The raw data
obtained from X-ray tomography and Magnetic Res-
onance Imaging (MRI) produce a 3D image demon-
strating a cartilage part, which could reconstruct a
cartilage defect. This image can then be 3D printed
using a vast variety of material combinations and tech-
niques to produce a porous matrix, where chondrocytes
can colonize. The whole process can take place in a
bioreactor.
Table 1. Cell surface markers expressed by MSCs. Adapted
by Zimmerlin et al., Haynesworth et al., and Le Blanck at
al.17-19
Cell surface markers expressed on mesenchymal stem cells.
Positive MHC class 1, HLA-ABC, CD13, CD29, CD34,
CD44, CD71, CD73, CD90, CD105, CD106,
CD166, Stro-1, VCAM-1, ALCAM-1, ICAM-1
Negative MHC class II, HLA-DR, HLA-DP, CD11, CD14,
CD18, CD31, CD34, CD38, CD40, CD45, CD80,
CD86, CD106
Materials and Methods
Cell Isolation and expansion 
Adipose tissues were collected after informed consent
of all donors and in accordance with the institutional
bioethics committee. Human adipose derived mes-
enchymal stem cells (AD-MSCs) were isolated from
adipose tissue by enzymatic dissociation. In particular,
the tissue sample was extensively washed with PBS
(GIBCO, Thermo Fisher Scientific, Waltham, MA
USA) containing penicillin/streptomycin (P/S) (Sig-
ma-Aldrich, St. Louis, MO, USA) in order to remove
debris. The tissue was placed in a sterile petri dish
with 4mg/ml collagenase type I and 2mg/ml dispase
type II (Roche, Basel, Switzerland) prepared in α-
MEM medium (GIBCO, Thermo Fisher Scientific,
Waltham, MA USA) with P/S and using sterile surgical
blades (Paragon, UK) tissue was minced into small
segments. The sample was digested for 1h at 37oC
and in order to facilitate further the digestion the
sample was pipetted up and down with a 10 or 25ml
pipette several times intermittently. Single cell sus-
pension was obtained by passing the cells through a
70 μm cell strainer, avoiding the solid aggregates. AD-
MSCs were obtained by centrifugation at 1000 rpm
for 5min. The supernatant was removed and the pellet
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was resuspended with MSC medium (a-MEM, 15%
FBS (Gibco, Thermo Fisher Scientific, Waltham, MA
USA), 2mM Glutamine, 0.1mM L-ascorbic acid phos-
phate, 100U/ml penicillin, 100mg/ml streptomycin).
The primary cells were cultured in T75 flask (Corning,
Sigma-Aldrich, St. Louis, MO, USA) at 37ᵒ C and
5% CO2 for about 2 weeks until they reached conflu-
ency and were defined as passage 0. The cells, that
had a typical fibroblast-like spindle shape, were pas-
saged at a ratio of 1:3. The adherent AD-MSCs were
expanded and either assessed for gene expression and
cell surface marker expression or induced to differ-
entiate towards chondrogenic, adipogenic and os-
teogenic lineages. The cells used in subsequent ex-
periments were between passages 3 and 6.  
2. chArAcTerizATiOn 
Of undifferenTiATed Ad-Mscs
Flow cytometry was performed to identify the expres-
sion of specific cell surface antigens that are used as
markers for immunophenotypic characterisation of
AD-MSCs. 
The cells were harvested when reaching 90-100%
confluency. Sufficient volume of trypsin-EDTA was
added and the cells were placed in the incubator for
5 min. After verifying under the microscope that more
than 90% of the attached cells have become detached
from the surface, MSC medium was added in order
to allow the serum contained in the medium to neu-
tralize the trypsin reaction. The cells were centrifuged
at 1000 rpm for 5min, were resuspended in MSC medi-
um and were counted using trypan blue to determine
viability. Because there is no single marker to identify
AD-MSCs, a multicolor identification with a combi-
nation of fluorochrome-labeled antibodies for different
surface antigens was used. For each analysis of surface
epitope characterization cells were rinsed in PBS and
resuspended at a density of 0.3-0.5 x 106 cells/100μl
FACS buffer (0.1% sodium azide, 1% BSA in PBS).
Additionally, a sample containing untreated cell sus-
pension as a control for autofluorescence was pre-
pared. The cells were first blocked with 5μg of human
IgG (Sigma-Aldrich, St. Louis, MO, USA) for 15min
on ice and subsequently stained with the following
fluorochrome conjugated antibodies (all obtained
from Biolegend, San Diego, CA, USA): CD90-FITC
CD73-PE-Cy7 (both expressed by AD-MSC) and
CD45-APC (negative marker). For each sample the
7-Aminoactinomycin D (7-AAD) Viability Staining
Solution was also included in order to define a region
for live cells (dead cell exclusion). 7-AAD is a fluo-
rescent chemical compound with a strong affinity for
DNA, which can only pass through disrupted cell
membranes. Thus 7-AAD stains dead cells, while
living cells with intact cell membranes will remain un-
stained20. Cells were incubated with the above men-
tioned combinations of antibodies for 20 min in the
dark on ice. Stained cells were washed twice with
FACS buffer (PBS, 1% BSA) and analyzed. Guava
easyCyte flow cytometer (Merck-Millipore, Darm-
stadt, Germany) with the pre-installed software for
data acquisition and analysis was used. In addition,
quality control was performed by including the analysis
of fluorescent beads to validate the function of the
lasers before each analysis. A total of 10,000 events
were acquired for each sample. Unstained cells were
used as a control to set the gates and analysis region.
3. cell differenTiATiOn AssAys
A hallmark of MSCs is their multipotency, which
means that by using specific inductive culture media
it is possible to direct MSC differentiation to specific
cell types in vitro. However, not all MSCs in cultures
present this ability due to cellular senescence or lack
of optimal cocktail that drives differentiation. Based
on these observations a trilineage differentiation assay
of the AD-MSCs was performed in order to confirm
their multipotency.
a.Chondrogenic differentiation
AD-MSCs were seeded in 6-well plates until conflu-
ency and were differentiated into chondrocytes by
culturing the cells into chondrogenic differentiation
medium consisting of a-MEM supplemented with
15% FBS, 2mM Glutamine, 0.1mM L-ascorbic acid
phosphate, 100U/ml penicillin, 100mg/ml streptomycin,
ITS, 100nM dexamethasone and 10ng/mL transform-
ing growth factor-β1. Cells were cultured for 7, 14
and 21 days with the differentiation medium (medium
changes twice per week). Evaluation of the chondro-
genic differentiation was carried out by staining with
Toluidine blue (Sigma-Aldrich, St. Louis, MO, USA).
Cells were fixed in 10% formalin for 30min, washed
2 times with PBS and stained with 0.1% Toluidine
blue for 30min in order to highlight the presence of
proteoglycans and subsequently the level of chondro-
genic differentiation. Morphological changes could
be observed by comparing uninduced and induced
AD-MSCs. Gene expression analysis was also per-
formed as described below. 
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b. Osteogenic differentiation
The osteogenic differentiation capacity of AD-MSC
was investigated in cultures in the presence of os-
teogenic medium, a-MEM supplemented with 15%
FBS, 2mM Glutamine, 0.1mM L-ascorbic acid phos-
phate, 100U/ml penicillin, 100mg/ml streptomycin,
10nM dexamethasone (Sigma-Aldrich, St. Louis, MO,
USA), 1.8 mM KH2PO4 and 5mM glycerolphosphate
(Sigma-Aldrich, St. Louis, MO, USA). After culture
for 7, 14 and 21 days with the differentiation medium
(medium changes twice per week) calcium accumu-
lations were observed under the microscope. 
c. Adipogenic differentiation
The adipogenic differentiation capacity of AD-MSC
was investigated in the presence of adipogenic medi-
um, a-MEM supplemented with 15% FBS, 2mM G-
lutamine, 0.1mM L-ascorbic acid phosphate, 100U/ml
penicillin, 100mg/ml streptomycin, 0.5μM dexametha-
sone, 0.5mM IBMX (Sigma-Aldrich, St. Louis, MO,
USA), 10μg/ml insulin and 60 μM indomethacin (Sig-
ma-Aldrich, St. Louis, MO, USA). After culture for
7, 14 and 21 days with the differentiation medium
(medium changes twice per week) lipids droplets were
observed under the microscope.
4. MrnA isOlATiOn And reAl-TiMe 
rT-Pcr AssAys
Total mRNA was isolated using the NucleoSpin RNA
kit (Macherey-Nagel, Düren, Germany) according to
the manufacturer’s protocol and Epoch microplate
spectrophotometer was used to quantify RNA. cDNA
synthesis was performed by using 0.5μg RNA as tem-
plate and the PrimeScript RT reagent kit (Takara Shu-
zo Co., Kyoto, Japan). Real-Time PCR was carried
out in duplicate using KAPA SYBR Fast® Mix
(KK4601 Kapa Biosystems, Woburn, MA, USA) in
StepOne™ (Applied Biosystems, Thermo Fisher Sci-
entific, Waltham, MA USA). The PCR specifications
were as follows: 95°C for 10 minutes, 40 cycles for 5
seconds at 95°C, 60°C for 30 seconds. Beta-2 mi-
croglobulin (B2M) was used as reference gene and
aggrecan expression was used to confirm chondrogenic
differentiation.
5. scAffOld fAbricATiOn And cAd - cAM/
3d PrinTing
The integration of an advanced manufacturing
technique with a biocompatible biomaterial of con-
trolled porous architecture was investigated in this s-
tudy aiming to deliver a personalized septal cartilage
scaffold. Based on the Poly Lactic-Acid material PLA,
a three-dimensional scaffold with customized archi-
tecture, controlled porosity and totally interconnected
porous structure was successfully fabricated using
Fused Deposition Modeling (FDM) method, one of
the 3D printing techniques. 
For the experiment, firstly one porous scaffold
was designed using SolidWorks as a CAD software,
and afterwards the design was converted to an STL
format (STL being derived from the name Stere-
olithography). The STL file was then loaded to Slic3r
software for setting up the fabrication parameters.
The scaffold sliced into 9 layers and the infill param-
eters were set to, fill density: 22%, fill pattern: hon-
eycomb and the top/bottom fill pattern: rectilinear.
The temperatures of the liquefier and the heated bed
were set to 210oC and 50oC respectively. After settings,
G-Code was created and the septal cartilage was fab-
ricated with PRUSA I3, a 3D Printing machine.
resulTs
characterization of Ad-Mscs
After cellular adhesion, the cells displayed the typical
fibroblast-like spindle shape of MSCs (Fig 1). 
figure 1. Morphology of AD-MSC culture in vitro. 
The cultured AD-MSCs expressed the cell surface
markers CD90 and CD73 and were negative to CD45,
as it was expected based on the literature (Fig 2). The
absence of stained cells with 7-AAD viability staining
solution, confirmed the high viability of the evaluated
cell population.
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chondrogenic differentiation
After 7, 14 and 21 days of culturing in differentiation
media the AD-MSC were positively stained with tolu-
idine blue. Toluidine blue is a majorly used thiazine
metachromatic dye with high affinity for acidic tissue
components, thereby staining tissues rich in DNA and
RNA. When bound to cartilage, toluidine blue be-
comes from blue to red (depending on the Chondroitin
sulfate content)21. The expected colour change of the
stain was observed from day 7 to day 21 as the stem
cells were differentiated into chondrocytes (Fig 3). 
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figure 2. Characterization of AD-MSCs by flow cytometry. a) Gating b) Representative diagram showing the expression
of positive mesenchymal markers y-axis CD90 FITC, x-axis CD73 PE-Cy7, c) Representative diagram showing the expression
of the negative mesenchymal marker y-axis CD45 APC, and x-axis 7AAD Viability Staining Solution d) Representative
diagram showing the expression of the negative mesenchymal marker x-axis CD45-APC, and the positive marker y-axis
CD90-FTC.
For further characterisation of the chondrocytes,
at the mRNA level this time, Real-time PCR was per-
formed in total RNA at days 7, 14 and 21 after induc-
tion of differentiation. The mRNA of the gene ACAN
gene, which is expressed in cartilage, was increasing
during chondrogenic differentiation (Fig 4).
Three-dimensional septal cartilage design and
fabrication
An FDM 3D printing machine (PRUSA I3) and PLA
(Poly Lactic-Acid) as a material was used to fabricate
a septal cartilage scaffold to investigate cell biocom-
patibility and mechanical properties into a bioreactor
with different principles of bioprocesses. 
For the experiment, one porous scaffold was de-
signed using SolidWorks as CAD software and the
dimensions were based on the basic anatomy of a sep-
tal cartilage (Figure 5 and 6).
The design was exported into an STL format (STL
being derived from the name stereolithography) and
transferred to the Slic3r software to export the G-
code for 3D Printing. The infill settings that were used
for the pores of the scaffold are:
figure 4: Real-time PCR analysis of the chondrogenic ex-
pressed gene ACAN geneat at 7, 14 and 21 days post-induc-
tion. Results are normalized to the expression of the house-
keeping gene B2M
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figure 3. In vitro chondrogenic differentiation. AD-MSC s-
tained with the metachromatic stain toluidine blue for up to
21 days.
figure 5. Schematic of the computer aided design model in
2 dimensional view.
figure 6. Schematic of the computer aided design septal car-
tilage in 3 dimensional view.
Fill density: 22%
Fill pattern: Honeycomb 
Top/Bottom Fill pattern: rectilinear 
(Figures 7 and 8).
The scaffold model was sliced into 9 layers and it
was fabricated using the G-Code exported from Silc3R
(Fig. 9). The liquefier temperature was set at 2100 C
± 20 C and the platform temperature was set to 500
C. After the fabrication, the scaffold was removed
from the base and stored prior to usage.
discussiOn
Human adipose-derived MSCs are being isolated, cul-
tured in vitro and chondrogenic differentiation is in-
duced. The process of differentiation into cartilage
is monitored in different levels. The expression of
chondrocytic surface markers in protein level is proven
via flow cytometry and staining. While, the expression
of other genes representative of chondrocytes, such
as ACAN (aggreecan), is tested in mRNA level using
qPCR, showing the expected pattern of increasing ex-
pression.
In parallel, a three dimensional scaffold representing
precisely the morphology and size of a nasal septal car-
tilage was produced. CAD/CAM technology was used
to design of the scaffold which was subsequently man-
ufactured using 3D printing. The material used was
Poly Lactic-Acid (PLA), carefully chosen as a “study”
material for the purpose of translational research.
The next step in this study will be the in vitro co-
culture of the 3D chitosan/gelatine scaffold (still under
development) with the differentiated chondrocytes
in a perfusion bioreactor. During this process the cells
are expected to be embedded in the matrix and shape
a potential cartilage transplant. In the near future, s-
caffolds representing cartilage features of other body
parts with a high rate of defects, such as knee cartilage,
will be designed and produced.  The same technology
of 3D printing can be employed with other combina-
tions of materials, in pursuit of better mechanical
properties, biodegradability, and biocompatibility of
the transplants. Personalized cartilage scaffolds for
clinical use it is also possible and anticipated to be
more and more available as the methods are being
perfected.
Our first limitation of cartilage transplant produc-
tion is the chamber size of the bioreactor. In our com-
mercialised bioreactor (BOSE/TA instruments) only
small cartilage parts, size ranging to 2.5X2.5.bX8.0cm
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figure 7. Schematic of the porosity of the septal cartilage,
rectilinear.
figure 8. Schematic of the porosity of septal cartilage, hon-
eycomb.
figure 9: Polymer scaffold of septal cartilage.
can be cultured, restricting the options. To overcome
this limitation we are aiming to design and produce
via 3D printing new bigger chambers, appropriate to
host scaffolds of any possible size and morphology. 
This state-of-the-art technology has being made
possible after the implementation of the project
REMEDIC (www.remedicproject.eu), which provided
for the School of Medicine of the Aristotle University
a complete functional unit of Regenerative Medicine.
The programme has also provide funds for transla-
tional research that is now being carried out aiming
to knowledge dissemination new skills development
and keeping our Scholl updated and competitive with
respect to Regenerative Medicine research.
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Mεταφραστική έρευνα για την αναγέννηση ρινικού διαφράγματος
με χονδροκύτταρα προερχόμενα από διαφοροποιημένα μεσεγυματικά
βλαστικά κύτταρα λιπώδους ιστού ανθρώπου
Βασιλική-Ίλυα Γαργαρέτα1, Στέλλα-Μαρία Καραγιαννάκη1, Mαρία Χναράκη1, 
Kωνσταντίνος Θεοδωρίδης1, Γεωργία Κατσιούδη1, Eλένη Αγγελίδου1, Θεοφάνης Βαβίλης1,
Πέτρος Κοΐδης2, Mαρία-Ελένη Μάνθου5, Mαρία Χατζηνικολαΐδου3,4, 
Aθηνά Μπακοπούλου2 και Αριστείδης Κριτής1
Περίληψη: Η εργασία αφορά στη μεταφραστική έρευνα ιστοτεχνολογίας και συγκεκριμένα στη δημιουργία ανθρώπινου
ρινικού διαφράγματος με τη χρήση ηλεκτρονικά υποβοηθούμενου σχεδιασμού και τρισδιάστατης εκτύπωσης τρισδιάστατου
(3D) πορώδους ικριώματος χιτοζάνης/ζελατίνης (CAD/CAM). Το ικρίωμα θα χρησιμοποιηθεί για να αποικιστεί από χρον-
δροκύτταρα που προκύπτουν από διαφοροποιημένα μεσεγχυματικά κύτταρα ανθρώπου προερχόμενα από λιπώδη ιστό
(Adipose Tissue Mesenchymal Stem Cells-AD- MSCs). Η όλη διαδικασία επιτυγχάνεται με τη χρήση βιοαντιδραστήρα.
Τα μεσεγχυματικά κύτταρα είναι πολυδύναμα βλαστοκύτταρα που μπορούν να απομονωθούν από το μυελό των οστών
και το λιπώδη ιστό. Τα κύτταρα αυτά έχουν τη δυνατότητα να διαφοροποιούνται, υπό εργαστηριακές συνθήκες, σε οστε-
οκύτταρα, χονδροκύτταρα, και λιποκύτταρα. Στην παρούσα μελέτη ανθρώπινα μεσεγχυματικά κύτταρα απομονώθηκαν
από λιπώδη ιστό και καλλιεργήθηκαν in vitro. Η έκφραση των αντιγόνων επιφανείας CD90, CD73, σε συνδυασμό με την
απουσία του μάρτυρα CD45 επιβεβαιώνουν την επιτυχή απομόνωση μεσεγχυματικών βλαστικών κυττάρων, με χρήση κυτ-
ταρομετρίας ροής. Έπειτα από 21 ημέρες από την επαγωγή στοχευόμενης διαφοροποίησης τα βλαστοκύτταρα διαφορο-
ποιήθηκαν σε χονδροκύτταρα και χαρακτηρίστηκαν ιστολογικά με χρώση κυανού της τολουιδίνης και μοριακά με RT-
PCR για δείκτες διαφοροποίησης όπως η αγκρεκάνη. Με τη χρήση του τρισδιάστατου εκτυπωτή δημιουργήθηκε υπό
κλίμακα ικρίωμα ρινικού χόνδρου από PLA. Η διαδικασία θα ολοκληρωθεί με την εκτύπωση του υπό διερεύνηση υλικού
χιτοζάνης/ζελατίνης σε 3D ικρίωμα και αφού εμποτιστεί με χονδροκύτταρα θα μεταφερθεί στον βιοαντιδραστήρα.
1. Harichandan A, Sivasubramaniyan K, Bühring H-J.
Prospective isolation and characterization of human bone
marrow-derived MSCs.  Mesenchymal Stem Cells-Basics
and Clinical Application I: Springer; 2012. p. 1-17.
2. Minteer D, Marra KG, Rubin JP. Adipose-derived mes-
enchymal stem cells: biology and potential applications.
Mesenchymal Stem Cells-Basics and Clinical Application
I: Springer; 2012. p. 59-71.
3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Dou-
glas R, Mosca JD, et al. Multilineage potential of adult
human mesenchymal stem cells. science. 1999;284(5411):
143-7.
4. Wakitani S, Saito T, Caplan AI. Myogenic cells derived
from rat bone marrow mesenchymal stem cells exposed
to 5ᵒazacytidine. Muscle & nerve. 1995;18(12):1417-26.
5. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Ver-
faillie CM. Purification and ex vivo expansion of postnatal
human marrow mesodermal progenitor cells. Blood.
2001;98(9):2615-25.
6. Inui A, Iwakura T, Reddi AH. Human stem cells and ar-
ticular cartilage regeneration. Cells. 2012;1(4):994-1009.
7. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bel-
lantuono I, Fisk NM. Identification of mesenchymal
stem/progenitor cells in human first-trimester fetal blood,
liver, and bone marrow. Blood. 2001;98(8):2396-402.
8. Chamberlain G, Fox J, Ashton B, Middleton J. Concise
review: mesenchymal stem cells: their phenotype, differ-
entiation capacity, immunological features, and potential
for homing. Stem cells. 2007;25(11):2739-49.
9. Kock L, van Donkelaar CC, Ito K. Tissue engineering
of functional articular cartilage: the current status. Cell
and tissue research. 2012;347(3):613-27.
10. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem
cells: paradoxes of passaging. Experimental hematology.
2004;32(5):414-25.
11. Hofstetter C, Schwarz E, Hess D, Widenfalk J, El Manira
A, Prockop DJ, et al. Marrow stromal cells form guiding
strands in the injured spinal cord and promote recovery.
Proceedings of the National Academy of Sciences.
2002;99(4):2199-204.
12. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez
A, Sorg RV, et al. Repair of infarcted myocardium by
autologous intracoronary mononuclear bone marrow
cell transplantation in humans. Circulation. 2002;106(15):
1913-8.
13. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I,
Quaini F, et al. Mobilized bone marrow cells repair the
infarcted heart, improving function and survival. Pro-
ceedings of the National Academy of Sciences.
2001;98(18):10344-9.
14. Estes BT, Guilak F. Three-dimensional culture systems
to induce chondrogenesis of adipose-derived stem cells.
Adipose-Derived Stem Cells: Methods and Protocols.
2011:201-17.
15. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal
cells migrate throughout forebrain and cerebellum, and
they differentiate into astrocytes after injection into
neonatal mouse brains. Proceedings of the National A-
cademy of Sciences. 1999;96(19):10711-6.
16. Hunziker EB. Articular cartilage repair: basic science
and clinical progress. A review of the current status and
prospects. Osteoarthritis and cartilage. 2002;10(6):432-
63.
17. Zimmerlin L, Donnenberg VS, Pfeifer ME, Meyer EM,
Péault B, Rubin JP, et al. Stromal vascular progenitors
in adult human adipose tissue. Cytometry Part A.
2010;77(1):22-30.
18. Haynesworth SE, Barer M, Caplan AI. Cell surface anti-
gens on human marrow-derived mesenchymal cells are
detected by monoclonal antibodies. Bone. 1992;13(1):69-
80.
19. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E,
Ringdén O. HLA expression and immunologic proper-
tiesof differentiated and undifferentiated mesenchymal
stem cells. Experimental hematology. 2003;31(10):890-
6.
20. Schmid I, Krall WJ, Uittenbogaart CH, Braun J, Giorgi
JV. Dead cell discrimination with 7ᵒaminoᵒactinomcin
D in combination with dual color immunofluorescence
in single laser flow cytometry. Cytometry. 1992;13(2):204-
8.
21. Sridharan G, Shankar AA. Toluidine blue: a review of
its chemistry and clinical utility. Journal of Oral and Max-
illofacial Pathology. 2012;16(2):251.
Translational research for nasal cartilage regeneration with chondrocytes 9
references
